MULTI-OMIC CHARACTERIZATION OF PLASMA FROM PATIENTS DIAGNOSED WITH BLADDER CANCER REVEALS MOLECULAR INSIGHT INTO IMMUNITY AND RECEPTOR SIGNALING PATHWAYS

Importance of the Topic

Bladder cancer remains a significant clinical challenge with rising incidence and mortality rates worldwide. Developing non-invasive biomarkers to improve early detection, monitor disease progression, and understand underlying molecular mechanisms is critical for advancing patient care and personalized therapies.

Objectives and Study Overview

This work applied a combined proteomic, metabolomic, and lipidomic strategy to plasma samples from 12 individuals: healthy controls and patients diagnosed with bladder carcinoma. The study aimed to identify differentially expressed biomolecules, characterize multi-omic signatures, and map these changes onto biological pathways relevant to cancer immunity and receptor signaling.

Methodology

Sample Preparation and Extraction

• Proteomics: 20 µL of undepleted plasma reduced, alkylated, and trypsin-digested overnight.
• Metabolomics: Proteins precipitated with cold acetonitrile; supernatant used for analysis.
• Lipidomics: Extraction protocol following Sarafian et al. with organic solvent partitioning.

LC-MS Analysis

• Proteins: ACQUITY M-Class UPLC, 30 min gradient (1–40% acetonitrile with 0.1% formic acid) at 7 µL/min.
• Metabolites: ACQUITY I-Class UPLC with HILIC column, 6.5 min gradient (5–50% acetonitrile with ammonium formate) at 700 µL/min.
• Lipids: Reversed-phase UPLC, 20 min gradient (3–40% isopropanol:methanol with ammonium formate) at 400 µL/min.
• Mass Spectrometry: Xevo G2-XS QToF in SONAR™ data-independent acquisition mode.

Data Processing and Statistics

• Progenesis software for peak alignment, feature detection, and normalization.
• Multivariate analysis (PCA, ANOVA, fold-change filtering) using EZInfo.
• Pathway mapping via MetaCore to link signatures to immune and lipid transport pathways.

Instrumentation Used

• Waters ACQUITY M-Class and I-Class UPLC systems
• Xevo G2-XS QToF mass spectrometer (SONAR™ mode)
• Standard laboratory centrifuges and sample preparation equipment

Key Results and Discussion

Proteomic Findings

• Elevated acute-phase proteins: C-reactive protein (CRP) and haptoglobin (HP) showed significant overexpression in cancer plasma.
• Growth factor regulators: Increased levels of insulin-like growth factor binding protein 3 (IGFBP3) and DNA damage checkpoint protein RAD9.
• Apolipoproteins: A broad upregulation of Apo C-II, C-III and related family members in bladder cancer samples, independent of body mass index.

Lipidomic and Metabolomic Findings

• Cholesterol derivatives: Significant rise in glucosyl-cholesterol species (16:2 and 16:0 glyco-cholesterols) in patient plasma.
• Triglycerides: TAG (50:3) and other polyunsaturated species were consistently elevated in cancer samples.
• PCA separation: Clear discrimination between healthy and cancer cohorts based on multi-omic profiles.

Pathway Insights

• IL-6 mediated acute-phase response: Proteomic changes align with inflammatory signaling circuits in hepatocytes.
• HDL-mediated reverse cholesterol transport: Lipid alterations map to disrupted cholesterol handling pathways in tumor biology.

Benefits and Practical Applications

The multi-omic panel offers a robust platform to discover plasma biomarkers for early bladder cancer detection, risk stratification, and therapeutic monitoring. Integration of protein and lipid signatures provides insight into tumor-driven inflammation and altered lipid metabolism, suggesting targets for personalized interventions.

Future Trends and Potential Applications

Advancing this approach will involve expanding patient cohorts, validating biomarker panels in larger clinical trials, and integrating genomic data for comprehensive tumor profiling. Emerging high-throughput MS technologies and machine learning may further refine predictive models and support real-time patient monitoring.

Conclusion

This study demonstrates the power of combining proteomics, metabolomics, and lipidomics to reveal distinct molecular signatures in bladder cancer patient plasma. The identified biomarkers and pathway associations lay the groundwork for diagnostic assays and deepen mechanistic understanding of cancer-related immunity and lipid signaling.

References

1. American Cancer Society. Key statistics for bladder cancer. 2019.
2. Sarafian et al. Optimization of sample preparation for untargeted plasma lipid profiling. Anal Chem. 2014;86(12):5766–5774.
3. Gethings et al. Lipid profiling using SONAR™ data-independent acquisition. Rapid Commun Mass Spectrom. 2017;31(19):1599–1606.
4. Moseley et al. Scanning Quadrupole DIA: Qualitative and quantitative characterization. J Proteome Res. 2018;17(2):770–779.